Maternal health and drug development

Preeclampsia Drug Development: Can sFlt-1 and VGLL3 Therapies Give Families More Time?

Explore preeclampsia treatment research targeting sFlt-1 and VGLL3, the limits of early-stage evidence, maternal–fetal safety and equitable trial access.

By Lampgen Clinical Research

Conceptual placental vascular illustration, molecular particles and an expectant mother silhouette beneath the question: Can targeted therapies change the timeline?
AI-generated conceptual illustration for Lampgen Clinical Insights. This is not an anatomical diagram or actual participant; clinical benefit of investigational therapies remains unproven.

5 min read · estimated

Sources
sFlt-1VGLL3
Distinct investigational targets; no disease-modifying therapy is yet approved for preeclampsia

What the source reported

At 27 weeks pregnant, Emily Chaddock experienced severe preeclampsia. Her daughter, Mia Springer, was born weighing less than two pounds. Kyle LaHucik's November 5, 2026 Endpoints News feature describes the family's experience and the lasting consequences of that premature birth. It is a reminder that the clinical challenge is not abstract: the lives and health of two patients can depend on decisions made over hours or days. This article is independent analysis based on that reporting and the underlying scientific and clinical sources; it does not reproduce the original feature. [1]

Preeclampsia is a pregnancy-specific disorder involving high blood pressure and potentially serious injury to the kidneys, liver, brain and other organs. Blood-pressure medication, seizure prevention and close monitoring can address risks, and low-dose aspirin can reduce risk for certain pregnant people before disease develops. But there is still no approved disease-modifying medication that reliably reverses established preeclampsia. Delivery of the baby and placenta remains the definitive intervention, sometimes at a gestational age when prematurity creates substantial risk. The condition can also occur or persist postpartum. [2]

A central biological hypothesis concerns soluble fms-like tyrosine kinase-1, or sFlt-1, an anti-angiogenic protein released in excess by the placenta. Elevated sFlt-1 disrupts vascular signaling and is implicated in maternal endothelial dysfunction. Comanche Biopharma is developing investigational CBP-4888, a small interfering RNA (siRNA) designed to lower excess placental sFlt-1 production. Its clinical program includes a dose-finding Phase 1 study in hospitalized people with preterm preeclampsia who are considered clinically stable for expectant management. The registered study evaluates safety, tolerability, pharmacokinetics and pharmacodynamics; it does not yet establish a safe extension of pregnancy or improved infant outcomes. Mothers are monitored after delivery and infants are followed for up to 24 months. [3, 4]

Another strategy is to remove circulating sFlt-1. A 2026 Nature Medicine pilot study investigated a specialized apheresis procedure to filter this protein from maternal blood. The study observed reductions in circulating sFlt-1 and blood pressure, but its small, early design cannot demonstrate that the intervention improves pregnancy duration or long-term outcomes. Separately, Avilar Therapeutics reported preclinical results from an sFlt-1-targeted protein degrader, including nonhuman-primate findings. The Avilar candidate has not demonstrated clinical safety or efficacy in pregnant patients. [5, 6]

A different line of research seeks to act further upstream. A 2026 Circulation study using human placental tissue, molecular profiling and animal models identified VGLL3 as a regulator linked to abnormal placental differentiation, inflammatory signaling and endothelial dysfunction. The investigators found that VGLL3 acts upstream of sFlt-1-associated processes. PreEmpt Bio is pursuing VGLL3-targeted treatments. The published evidence supports a therapeutic hypothesis; it is not proof that VGLL3 inhibition prevents or treats human preeclampsia. [7, 8]

What this means for trial teams

The potential clinical advance is a change in the decision framework. Today, when preeclampsia threatens a very premature pregnancy, clinicians must continually weigh maternal deterioration against the hazards of early delivery. A proven therapy that safely controls disease biology might, in selected patients, allow additional fetal development without compromising maternal health. That is a potential outcome to test—not an outcome already shown for any investigational candidate.

Clinical trial design must treat the pregnant participant and developing child as two linked safety populations. Protocols need explicit maternal stopping rules; rapid escalation pathways for severe hypertension, neurological symptoms and laboratory deterioration; fetal surveillance plans; and independent safety review. A drug's ability to lower a biomarker cannot substitute for evidence of clinical benefit and acceptable risk. Gestational age at diagnosis, sFlt-1/PlGF biomarker criteria, disease severity and concurrent standard-of-care treatment all matter when evaluating results.

Follow-up must extend beyond the treatment window. Even if a therapy safely prolongs gestation, teams will need to assess delivery circumstances, birth weight, neonatal morbidity, developmental outcomes and possible later maternal complications. Comanche's infant follow-up through 24 months illustrates why early maternal pharmacodynamic results are only one part of the evidence picture. Sites will need coordination among maternal–fetal medicine, pharmacy, neonatal services, study coordinators, monitors and long-term follow-up teams.

Equity is not an optional supplement to these protocols. CDC data for all-cause maternal mortality in 2024 show 44.8 deaths per 100,000 live births among non-Hispanic Black women versus 14.2 among non-Hispanic White women. These figures are not preeclampsia-specific, and they should not be presented as if they were. They nevertheless underscore the need to study whether diagnostic access, site geography, referral patterns, language, transportation and postpartum continuity affect who can participate and who might eventually benefit. [9]

For sponsors and CROs, staffing is a scientific and safety decision. Clinical research associates should be matched to the protocol's actual demands, including informed-consent documentation, biomarker eligibility, maternal/fetal assessment timing, safety reporting and multi-service data reconciliation. Clinical trial managers must clarify site capacity, communication and escalation ownership, and the feasibility of retention across pregnancy and infancy. Investigators and qualified medical teams—not CRAs—make clinical judgments and treatment decisions.

Lampgen Clinical Research specializes in oncology CRA staffing and provides clinical-operations support. Our operational perspective applies across therapeutic areas: an exciting mechanism is only the beginning. Translating it into trustworthy evidence requires patient-centered protocols, experienced teams and safeguards that make both immediate safety and long-term outcomes visible. We do not suggest that Lampgen is involved in the trials discussed.

The most important question is not simply whether a drug can change sFlt-1 or VGLL3 signaling. It is whether the intervention can safely improve the lives of mothers and babies in a way that remains reproducible, accessible and meaningful beyond a laboratory or early-phase result. The accompanying AI-generated image is a conceptual scientific illustration, not an anatomical diagram or depiction of an actual participant or therapeutic effect.

Sources

  1. 1. Kyle LaHucik, Endpoints News feature, November 5, 2026 (article indexed by Muck Rack)
  2. 2. NIH NICHD — preeclampsia treatment and delivery decisions
  3. 3. Comanche Biopharma — CBP-4888 research and development
  4. 4. ClinicalTrials.gov — CBP-4888, NCT07282171
  5. 5. Nature Medicine (2026) — pilot study of targeted sFlt-1 apheresis
  6. 6. Avilar Therapeutics — preclinical sFlt-1 degrader report, October 8, 2026
  7. 7. Circulation (2026) — VGLL3-centered placental gene network
  8. 8. PreEmpt Bio — statement on VGLL3 research
  9. 9. CDC NCHS — 2024 U.S. maternal mortality rates, published March 2026

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?